- Home
- ADAP
as 01-17-2025 4:00pm EST
Adaptimmune Therapeutics PLC is a clinical-stage biopharmaceutical company. It focused on providing novel cell therapies to patients, particularly in solid tumors. It has developed a comprehensive proprietary platform that enables it to identify cancer targets, find and genetically engineer T-cell receptors, and produce TCR therapeutic candidates for administration to patients. Its programs include MAGE-A4 SPEAR T-cell therapy, NY-ESO SPEAR T-cell, CD70 and others for multiple cancer types.
| Founded: | 2008 | Country: | United Kingdom |
| Employees: | N/A | City: | ABINGDON, OXFORDSHIRE |
| Market Cap: | 158.6M | IPO Year: | 2015 |
| Target Price: | $2.79 | AVG Volume (30 days): | 2.3M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 4 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.18 | EPS Growth: | N/A |
| 52 Week Low/High: | $0.53 - $2.05 | Next Earning Date: | 03-05-2025 |
| Revenue: | $175,041,000 | Revenue Growth: | 146.27% |
| Revenue Growth (this year): | 204.91% | Revenue Growth (next year): | -78.17% |
Stock Insider Trading Activity of Adaptimmune Therapeutics plc (ADAP)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Piccina Cintia | ADAP | Chief Commercial Officer | Jan 15 '25 | Sell | $0.57 | 12,991 | $7,467.23 | 18,421 | |
| Rawcliffe Adrian | ADAP | Chief Executive Officer | Jan 13 '25 | Sell | $0.58 | 59,569 | $34,639.46 | 25,711 | |
| Lunger John | ADAP | Chief Patient Supply Officer | Jan 13 '25 | Sell | $0.58 | 19,542 | $11,360.32 | 7,623 | |
| Norry Elliot | ADAP | Chief Medical Officer | Jan 13 '25 | Sell | $0.58 | 22,195 | $12,920.02 | 5,845 | |
| Bertrand William C JR | ADAP | Chief Operating Officer | Jan 13 '25 | Sell | $0.58 | 19,542 | $11,360.32 | 7,623 |
Latest Adaptimmune Therapeutics plc News
ADAP Breaking Stock News: Dive into ADAP Ticker-Specific Updates for Smart Investing
Newsfile
6 days ago
Adaptimmune Announces U.S. FDA Breakthrough Therapy Designation Granted to Letetresgene Autoleucel (lete-cel) for Treatment of Myxoid/Round Cell Liposarcoma (MRCLS)
MT Newswires
a month ago
Adaptimmune Therapeutics Chief Financial Officer Gavin Wood to Resign in May 2025
Newsfile
a month ago
Adaptimmune Announces Changes to its Executive Leadership Team Based in The UK
Newsfile
2 months ago
First Patient Treated with Adaptimmune's TECELRA(R) (afamitresgene autoleucel)
MT Newswires
2 months ago
Mizuho Cuts Price Target on Adaptimmune Therapeutics to $1.50 From $3, Keeps Outperform Rating
Simply Wall St.
2 months ago
Adaptimmune Therapeutics Third Quarter 2024 Earnings: Beats Expectations
BioPharma Dive
2 months ago
Halozyme bids for Evotec; BeiGene gets a new name
Pharmaceutical Technology
2 months ago
Adaptimmune nears second sarcoma approval as Phase II trial hits endpoints
Compare ADAP vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "ADAP Adaptimmune Therapeutics plc - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.